Psychosocial domain in quality of life as an independent prognostic factor for survival and tumor response in patients with advanced non-small cell lung cancer (NSCLS)

Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 271
Author(s):  
T Matsumoto ◽  
K Kobayashi ◽  
K Eguchi ◽  
M Shibuya ◽  
S Morita ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Psychosocial Domain

scholarly journals Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer

2009 ◽  
Vol 4 (9) ◽  
pp. 1075-1082 ◽  
Author(s):  
Yingwei Qi ◽  
Steven E. Schild ◽  
Sumithra J. Mandrekar ◽  
Angelina D. Tan ◽  
James E. Krook ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung

Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial

2005 ◽  
Vol 23 (13) ◽  
pp. 2946-2954 ◽  
Author(s):  
David Cella ◽  
Roy S. Herbst ◽  
Thomas J. Lynch ◽  
Diane Prager ◽  
Chandra P. Belani ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Response ◽  
Small Cell ◽  
Symptom Improvement ◽  
Small Cell Lung

Purpose Evaluation of disease-related symptom improvement rate by the Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire was a coprimary end point of the pivotal phase II trial of gefitinib (Iressa; AstraZeneca, Wilmington, DE) conducted in the United States. This report includes the results of analyses exploring the relationship between weekly LCS scores and radiographic response and survival, as well as detailed protocol-specified analysis of symptom and quality-of-life data. Patients and Methods In this trial, 216 symptomatic patients with advanced non-small-cell lung cancer (NSCLC) who had at least two prior chemotherapy regimens received gefitinib 250 or 500 mg/d. Disease-related symptoms were assessed weekly and quality of life was assessed monthly by LCS and FACT-L, respectively. Results Symptom improvement was rapid and correlated with tumor response and survival. At the recommended gefitinib dose of 250 mg/d, median overall survival times were 13.6 and 4.6 months for patients with and without symptom improvement, respectively, and 9.7 months for patients with symptom improvement without tumor response. Among patients with stable disease or disease progression, those with symptom improvement had significantly better overall survival than those without improvement. At 250 mg/d, 30% of patients showed a quality-of-life improvement that was correlated with tumor response. Conclusion This triadic analysis of response, survival, and symptom data supports the hypothesis that tumor response and symptom response are related and that each predicts survival. Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression.

Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer

2012 ◽  
Vol 20 (6) ◽  
pp. 1941-1948 ◽  
Author(s):  
Óscar Arrieta ◽  
Laura P. Angulo ◽  
Carolina Núñez-Valencia ◽  
Yuzmiren Dorantes-Gallareta ◽  
Eleazar O. Macedo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Treatment Adherence ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Depression And Anxiety ◽  
Small Cell Lung

Quality Trials and Quality of Life in Non–Small-Cell Lung Cancer

2003 ◽  
Vol 21 (16) ◽  
pp. 3007-3008 ◽  
Author(s):  
Peter Harper ◽  
Tim Plunkett ◽  
David Khayat
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document